Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia.
Pediatr Hematol Oncol
; 39(2): 187-192, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-34369835
ABSTRACT
A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and highdose intravenous immunoglobulin lead to a resolution of the symptoms.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Guillain-Barré
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article